Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 12/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | MMP1 | P03956 | 6/20 | 0.50 |
| ▸ | MMP3 | P08254 | 2/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.49 |
| ▸ | MMP7 | P09237 | 1/20 | 0.49 |
| ▸ | MMP8 | P22894 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2778896 | 1.00 | CCR2 (0.53) | CCR2HTTMMP1MMP3MMP2 | |
| SCHEMBL8358035 | 1.00 | CCR2 (0.53) | CCR2HTTMMP1MMP3MMP2 | |
| SCHEMBL17149319 | 0.87 | CCR2 (0.40) | CCR2HTTMMP1MMP3MMP2 | |
| SCHEMBL17149318 | 0.87 | CCR2 (0.40) | CCR2HTTMMP1MMP3MMP2 | |
| SCHEMBL14040506 | 0.87 | CCR2 (0.40) | CCR2HTTMMP1MMP3MMP2 | |
| SCHEMBL4006271 | 0.83 | CCR2 (0.54) | CCR2HTTMMP1MMP3MMP2 | |
| SCHEMBL9508026 | 0.82 | HTT (0.58) | CCR2HTTRAB9A | |
| SCHEMBL8365578 | 0.82 | HTT (0.58) | CCR2HTTRAB9A | |
| SCHEMBL278259 | 0.80 | CCR2 (0.54) | CCR2HTTMMP1MMP3MMP2 | |
| SCHEMBL10824810 | 0.80 | CCR2 (0.49) | CCR2HTTMMP1MMP3MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2064177-B1 | PROTEASE INHIBITORS | TAIMED BIOLOGICS INC (TW) | 2017-04-05 | — | — | EP | disclosed |
| EP-2165709-B1 | Pharmaceutical compositions comprising a lysine based compound and an HIV antiviral or antiretroviral agent | AMBRILIA BIOPHARMA INC (CA) | 2016-03-16 | — | — | EP | disclosed |
| US-8742158-B2 | Protease inhibitors | TaiMed Biologies, Inc. (TW) | 2014-06-03 | — | — | US | disclosed |
| US-8742158-B2 | Protease inhibitors | TaiMed Biologies, Inc. (TW) | 2014-06-03 | — | — | US | disclosed |
| US-8580995-B2 | Lysine-based prodrugs of aspartyl protease inhibitors and processes for their preparation | TAIMED BIOLOGICS, INC. (TW) | 2013-11-12 | — | — | US | disclosed |
| US-8580995-B2 | Lysine-based prodrugs of aspartyl protease inhibitors and processes for their preparation | TAIMED BIOLOGICS, INC. (TW) | 2013-11-12 | — | — | US | disclosed |
| US-20130158261-A1 | PROTEASE INHIBITORS | TAIMED BIOLOGICS, INC. (TW) | 2013-06-20 | — | — | US | disclosed |
| US-20130158261-A1 | PROTEASE INHIBITORS | TAIMED BIOLOGICS, INC. (TW) | 2013-06-20 | — | — | US | disclosed |
| US-8410300-B2 | Protease inhibitors | TAIMED BIOLOGICS, INC. (TW) | 2013-04-02 | — | — | US | disclosed |
| US-8410300-B2 | Protease inhibitors | TAIMED BIOLOGICS, INC. (TW) | 2013-04-02 | — | — | US | disclosed |
| US-7388008-B2 | Lysine based compounds | AMBRILIA BIOPHARMA INC. (CA) | 2008-06-17 | — | — | US | disclosed |
| WO-2008023273-A2 | METHOD FOR IMPROVING PHARMACOKINETICS | AMBRILIA BIOPHARMA INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| EP-1877091-A1 | METHOD FOR IMPROVING PHARMACOKINETICS OF PROTEASE INHIBITORS AND PROTEASE INHIBITOR PRECURSORS | Ambrilia Biopharma Inc. (CA) | 2008-01-16 | — | — | EP | disclosed |
| WO-2007062526-A1 | LYSINE-BASED PRODRUGS OF ASPARTYL PROTEASE INHIBITORS AND PROCESSES FOR THEIR PREPARATION | AMBRILIA BIOPHARMA INC. (CA) | 2007-06-07 | — | — | WO | disclosed |
| WO-2006114001-A1 | METHOD FOR IMPROVING PHARMACOKINETICS OF PROTEASE INHIBITORS AND PROTEASE INHIBITOR PRECURSORS | AMBRILIA BIOPHARMA INC. (CA) | 2006-11-02 | — | — | WO | disclosed |
| WO-2006114001-A1 | METHOD FOR IMPROVING PHARMACOKINETICS OF PROTEASE INHIBITORS AND PROTEASE INHIBITOR PRECURSORS | AMBRILIA BIOPHARMA INC. (CA) | 2006-11-02 | — | — | WO | disclosed |
| US-6638921-B1 | Pharmaceutically acceptable derivatives thereof Cx, R1 and R2 being as defined in the disclosure may be used to inhibit the activity of HIV integrase. | PHARMACOR INC. (CA) | 2003-10-28 | — | — | US | disclosed |
| US-6632816-B1 | Aromatic derivatives as HIV aspartyl protease inhibitors | PHARMACOR INC. (CA) | 2003-10-14 | — | — | US | disclosed |
| US-6632816-B1 | Aromatic derivatives as HIV aspartyl protease inhibitors | PHARMACOR INC. (CA) | 2003-10-14 | — | — | US | disclosed |
| WO-2003082881-A2 | PYRIDOXAL-5-PHOSPHATE DERIVATIVES AS HIV INTEGRASE INHIBITORS | PROCYON BIOPHARMA INC. (CA) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158261-A1 | PROTEASE INHIBITORS | PREP, CTRL, CTRB1 | CCR2 305/4885HTT 3852/4885MMP1 573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.